Synapse - Maura Dickler

Results (263)

Change in circulating endothelial cells (CEC) predicts progression free survival (PFS) in patients (pts) with hormone receptor positive metastatic breast cancer (MBC) receiving letrozole (L) and bevacizumab (B)

Meeting Abstract

Rugo, H. S.; Dickler, M. N.; Traina, T. A.; Scott, J. H.; Moore, D. H.; Bruckner, J.; Hudis, C.; Park, J. W.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

Mature cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)

Meeting Abstract

Dang, C.; Smith, K.; Fornier, M.; Sugarman, S.; Troso, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; George, R.; more...
Breast Cancer Research and Treatment (2006)

Fulltext@MSK | Save

Small-fiber neuropathy associated with capecitabine (Xeloda)-induced hand-foot syndrome: A case report

Journal Article

Stubblefield, M. D.; Custodio, C. M.; Kaufmann, P.; Dickler, M. N.
Journal of Clinical Neuromuscular Disease (2006)

Fulltext@MSK | Save

A phase II trial of letrozole in combination with bevacizumab, an anti-VEGF antibody, in patients with hormone receptor-positive metastatic breast cancer

Meeting Abstract

Traina, T. A.; Dickler, M. N.; Caravelli, J. F.; Yeh, B. M.; Brogi, E.; Panageas, K.; Flores, S. A.; Norton, L.; Park, J.; Hudis, C.; more...
Breast Cancer Research and Treatment (2005)

Fulltext@MSK | Save

A feasibility study of an aromatase inhibitor (Al), letrozole (L) and the antibody to vascular endothelial growth factor (VEGF), bevacizurnab (B), in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC)

Meeting Abstract

Traina, T. A.; Dickler, M. N.; Caravelli, J. F.; Yeh, B. M.; Brogi, E.; Panageas, K.; Flores, S. A.; Norton, L.; Hudis, C.; Rugo, H.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Change in circulating endothelial cells (CEC) and tumor cells (CTC) in patients (pts) receiving bevacizumab and erlotinib for metastatic breast cancer (MBC) predicts stable disease at first evaluation

Meeting Abstract

Rugo, H. S.; Dickler, M. N.; Scott, J. H.; Moore, D. H.; Melisko, M.; Yeh, B. M.; Caravelli, J.; Brogi, E.; Hudis, C.; Park, J. W.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: A randomized, phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100)

Meeting Abstract

Miller, K.; Wang, M.; Gralow, J.; Dickler, M.; Cobleigh, M. A.; Perez, E. A.; Shenkier, T. N.; Davidson, N. E.
EJC Supplements (2005)

Fulltext@MSK | Save

A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100)

Meeting Abstract

Miller, K. D.; Wang, M.; Gralow, J.; Dickler, M.; Cobleigh, M. A.; Perez, E. A.; Shenkier, T. N.; Davidson, N. E.
Breast Cancer Research and Treatment (2005)

Fulltext@MSK | Save

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer